You are using an older browser version. Please use a supported version for the best MSN experience.

Coronavirus: Oxford University researcher says vaccine may be out by end of the year

Tuko logo Tuko 21/07/2020 Asher Omondi
a man sitting on a bed: Coronavirus: Oxford University researcher says vaccine may be out by end of the year © Provided by Tuko Coronavirus: Oxford University researcher says vaccine may be out by end of the year

- The first clinical trials were done in South Africa and Brazil and showed people who received dose of AZD1222 developed antibodies

- The drug maker said the vaccine also produced a response in T- cells that attacked cells infected with viruses

- Globally, 8,936,004 out of 14,881,625 people had recovered from the infection while 613,996 died as on July 21

The University of Oxford in conjunction with pharmaceutical giant AstraZeneca has confirmed they have produced a potential coronavirus vaccine.

The drug known as ChAdOx1 nCoV-19 (AZD1222) will possibly be out by September or end of the year 2020 according to the university's lead researcher Adrian Hill.

Coronavirus as viewed using a microscope. Scientists rushing against time to find its cure. Photo: Centre for Disease Control and Prevention.

Source: UGC

“There might be a million doses manufactured by September: that now seems like a remarkable underestimate, given the scale of what’s going on. Certainly there’ll be a million doses around in September. What’s less predictable than the manufacturing scale-up is the incidence of disease, so when there’ll be an endpoint," he said.

The drug maker said the results confirmed a single dose of AZD1222 resulted in a four-fold increase in antibodies to virus protein in 95% of participants one month after injection.

A researcher at KEMRI. Over 500,000 people have died from coronavirus in the world. Photo: KEMRI.

Source: UGC

At least 1,000 participants who received the vaccine developed neutralising antibodies against COVID-19, however, those who got single injection did not produce antibodies.

According to the two institutions, the vaccine also produced a response in T- cells, a type of white blood cell that attacked cells infected with viruses, according to the paper.

The AstraZeneca CEO Pascal Soriot so far they had conducted phase one and two, saying the next phase will address safety and protection of people.

"So far so good in terms of the data we've produced. All this needs to translate into clinical protection. People need to be protected from infections, and that's what we want to demonstrate in our phase three program,"he said.

The third phase will move to the US and UK and will involve over 30,000 participants.

South Africa and Brazil were some of the countries affected by coronavirus where clinical trials for the vaccine were initiated in the early stages by June.

“This is a landmark moment for South Africa and Africa at this stage of the COVID-19 pandemic. As we enter winter in South Africa and pressure increases on public hospitals, now more than ever we need a vaccine to prevent infection by COVID-19," University of Witwatersrand's Shabir Madhi said in June.

Globally, 8,936,004 out of 14,881,625 people had recovered from the infection as on July 21.

The other 613,996 patients lost the battle.

Do you have a hot story or scandal you would like us to publish, please reach us through news@tuko.co.ke or WhatsApp: 0732482690 and Telegram: Tuko news.

Kamotho, Virginia and Tabitha meet in Court, media barred from covering the custody case | Tuko TV.

Subscribe to watch new videos
AdChoices
AdChoices
image beaconimage beaconimage beacon